TMS Modulation of Insula-related Brain Networks

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02689323

Acronym

TMS_INS

Enrollment

Registered

2016-02-23

Start date

2016-03-31

Completion date

2016-11-04

Last updated

2017-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects

Brief summary

The purpose of this study is to investigate the modulatory effects of repetitive transcranial magnetic stimulation (rTMS) on functional connectivity with the insula. Functional connectivity (FC) measures the interaction between brain regions, and recent neuroimaging studies have used FC to investigate how addiction affects FC among pertinent brain regions. rTMS, which can excite cortical neurons, has shown promise as a method to manipulate brain connectivity and could be used therapeutically to treat addiction. However, investigators first need more information on brain FC and how it relates to behavior, in order to guide rTMS target selection.

Interventions

DEVICErepeated transcranial magnetic stimulation

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DEVICE_FEASIBILITY

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

1. generally healthy 2. between the ages of 18-55 3. right-handed

Exclusion criteria

1. significant health problems (e.g., current and uncontrolled liver, lung, or heart problems) or presence of medical illness likely to alter brain morphology (including history of seizure, history of epilepsy in self or first degree relatives, stroke, brain surgery, head injury, and known structural brain lesion) 2. current diagnosis of Axis I psychiatric disorders (e.g., depression, anxiety disorder, schizophrenia) 3. meet DSM-5 criteria for current substance use disorder other than nicotine 4. use of psychoactive medications that would result in a positive urine drug screen 5. Current use of medications known to lower the seizure threshold 6. positive breath alcohol concentration 7. presence of conditions that would make MRI unsafe (e.g., metal implants, pacemakers) 8. among women, a positive urine pregnancy test 9. vision that cannot be corrected to 20/40

Design outcomes

Primary

Measure	Time frame
Change in functional connectivity strength measured with functional magnetic resonance imaging	baseline and 1 week

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026